We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+13.07%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$246M
AUM Growth
-$60.8M
Cap. Flow
-$70.1M
Cap. Flow %
-28.47%
Top 10 Hldgs %
67.39%
Holding
78
New
29
Increased
8
Reduced
16
Closed
23

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$13.8M
2
MRK icon
Merck
MRK
+$12.9M
3
SBRA icon
Sabra Healthcare REIT
SBRA
+$5.57M
4
CI icon
Cigna
CI
+$4.93M
5
ELV icon
Elevance Health
ELV
+$4.91M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$15.9M
2
TAK icon
Takeda Pharmaceutical
TAK
+$14.3M
3
BAX icon
Baxter International
BAX
+$12.6M
4
LLY icon
Eli Lilly
LLY
+$12.4M
5
QGEN icon
Qiagen
QGEN
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 73.98%
2 Real Estate 2.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
1
Labcorp
LH
$25B
$21.4M 8.69%
105,836
-7,357
-6% -$1.44M
CI icon
2
Cigna
CI
$73.7B
$16.5M 6.68%
49,678
+15,579
+46% +$4.93M
MRK icon
3
Merck
MRK
$322B
$14M 5.68%
+126,003
New +$12.9M
CNC icon
4
Centene
CNC
$30.7B
$13.8M 5.61%
+168,363
New +$13.8M
ELV icon
5
Elevance Health
ELV
$81.5B
$13.4M 5.43%
26,077
+9,675
+59% +$4.91M
ICLR icon
6
Icon
ICLR
$12.6B
$11.4M 4.65%
58,896
-7,541
-11% -$1.5M
AZN icon
7
AstraZeneca
AZN
$263B
$9.59M 3.89%
70,710
+20,186
+40% +$2.53M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.6B
$8.73M 3.55%
84,357
-61,017
-42% -$5.73M
SBRA icon
9
Sabra Healthcare REIT
SBRA
$5.34B
$5.43M 2.2%
+436,524
New +$5.57M
ELUT icon
10
Elutia
ELUT
$37.9M
$5.35M 2.17%
1,259,544
+119,612
+10% +$749K
INSM icon
11
Insmed
INSM
$21.4B
$4.86M 1.97%
243,122
+135,409
+126% +$2.62M
ALBO
12
DELISTED
Albireo Pharma Inc
ALBO
$4.69M 1.91%
217,209
+44,588
+26% +$942K
EHC icon
13
Encompass Health
EHC
$11B
$4.67M 1.9%
78,144
-4,785
-6% -$260K
RNAC icon
14
Cartesian Therapeutics
RNAC
$229M
$4.27M 1.73%
125,921
-5,359
-4% -$228K
VKTX icon
15
Viking Therapeutics
VKTX
$3.7B
$4.07M 1.65%
+433,035
New +$1.93M
COR icon
16
Cencora
COR
$60.6B
$3.49M 1.42%
+21,034
New +$3.32M
BNTX icon
17
BioNTech
BNTX
$22.9B
$3.25M 1.32%
+21,664
New +$3.33M
OCUL icon
18
Ocular Therapeutix
OCUL
$1.79B
$2.99M 1.21%
1,063,953
-342
-0% -$1.13K
ADAP
19
DELISTED
Adaptimmune Therapeutics
ADAP
$2.53M 1.03%
1,733,236
-55,281
-3% -$89.5K
ZTS icon
20
Zoetis
ZTS
$32.4B
$2.45M 1%
16,728
-27,558
-62% -$4.08M
STRO icon
21
Sutro Biopharma
STRO
$401M
$2.28M 0.92%
28,190
+1,522
+6% +$106K
QGEN icon
22
Qiagen
QGEN
$8.54B
$2.03M 0.83%
38,429
-248,192
-87% -$12.2M
THC icon
23
Tenet Healthcare
THC
$20.5B
$1.97M 0.8%
40,452
-30,083
-43% -$1.39M
BDX icon
24
Becton Dickinson
BDX
$45.6B
$1.72M 0.7%
6,761
-27,521
-80% -$6.5M
BIO icon
25
Bio-Rad Laboratories Class A
BIO
$8.71B
$1.64M 0.66%
3,893
-3,091
-44% -$1.25M
1
2 3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Endurant Capital Management held 78 positions worth $246M, down 20% from $307M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Endurant Capital Management withdrew a net $70.1M in Q4 2022, closing 23 positions and reducing 16 holdings. Its most notable exit was Humana, an estimated $15.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 77% a quarter earlier, followed by Real Estate.

Against the trend, Endurant Capital Management opened a new position in Centene worth $13.8M.

  • Endurant Capital Management's largest Q4 2022 buy was Centene: 168,363 shares worth $13.8M.
  • Endurant Capital Management added most to Cigna in Q4 2022, an estimated $4.93M increase.
  • Endurant Capital Management's biggest Q4 2022 reduction was Baxter International, cutting an estimated $12.6M.
  • Endurant Capital Management fully exited Humana in Q4 2022, selling an estimated $15.9M.
  • Endurant Capital Management's ten largest holdings make up 67% of its $246M portfolio in Q4 2022.
  • Endurant Capital Management opened 29 new positions and closed 23 in Q4 2022.
  • Endurant Capital Management's portfolio value fell 20% quarter-over-quarter to $246M.

Based on Endurant Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.